Bioarchitech
1 known investors
Bioarchitech develops multifunctional cancer immunotherapies derived from viral genetic code, including an intravenous engineered Vaccinia virus therapy (BA-V151) for metastatic cancer and a self-amplifying RNA intratumoural therapy (BA-R166) for early-stage cancers. Its candidates aim to both kill tumour cells and induce anti-tumour immunity, with initial focus on oesophageal and lung cancer.
Investors · 1
Frequently asked questions
- What does Bioarchitech do?
- Bioarchitech develops multifunctional cancer immunotherapies derived from viral genetic code, including an intravenous engineered Vaccinia virus therapy (BA-V151) for metastatic cancer and a self-amplifying RNA intratumoural therapy (BA-R166) for early-stage cancers. Its candidates aim to both kill tumour cells and induce anti-tumour immunity, with initial focus on oesophageal and lung cancer.
- Who are Bioarchitech's investors?
- Bioarchitech's investors include Oxford Technology Management.